Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 3.77
(-0.53%)
CNY 3.77
(-0.53%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.39 Billion CNY | -6.36% |
| 2022 | 2.56 Billion CNY | -19.87% |
| 2021 | 3.19 Billion CNY | 194.48% |
| 2020 | 1.08 Billion CNY | 135.17% |
| 2019 | 461.8 Million CNY | -48.52% |
| 2018 | 897.11 Million CNY | -33.0% |
| 2017 | 1.33 Billion CNY | 11.67% |
| 2016 | 1.19 Billion CNY | -8.39% |
| 2015 | 1.3 Billion CNY | 14.62% |
| 2014 | 1.14 Billion CNY | 25.82% |
| 2013 | 907.55 Million CNY | 103.63% |
| 2012 | 445.69 Million CNY | 699.1% |
| 2011 | 55.77 Million CNY | 17.18% |
| 2010 | 47.59 Million CNY | -85.22% |
| 2009 | 321.98 Million CNY | 12.46% |
| 2008 | 286.3 Million CNY | 61.29% |
| 2007 | 177.5 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.03 Billion CNY | -6.0% |
| 2024 Q1 | 2.18 Billion CNY | -9.03% |
| 2024 Q2 | 2.16 Billion CNY | -0.81% |
| 2023 Q1 | 2.49 Billion CNY | -2.58% |
| 2023 FY | 2.39 Billion CNY | -6.36% |
| 2023 Q2 | 2.65 Billion CNY | 6.54% |
| 2023 Q3 | 2.45 Billion CNY | -7.56% |
| 2023 Q4 | 2.39 Billion CNY | -2.39% |
| 2022 Q2 | 2.81 Billion CNY | -1.94% |
| 2022 Q4 | 2.56 Billion CNY | -0.13% |
| 2022 FY | 2.56 Billion CNY | -19.87% |
| 2022 Q3 | 2.56 Billion CNY | -8.92% |
| 2022 Q1 | 2.87 Billion CNY | -10.16% |
| 2021 Q3 | 3.35 Billion CNY | 52.38% |
| 2021 Q1 | 1.73 Billion CNY | 60.09% |
| 2021 Q2 | 2.2 Billion CNY | 26.54% |
| 2021 Q4 | 3.19 Billion CNY | -4.6% |
| 2021 FY | 3.19 Billion CNY | 194.48% |
| 2020 FY | 1.08 Billion CNY | 135.17% |
| 2020 Q3 | 582.47 Million CNY | 34.21% |
| 2020 Q2 | 434 Million CNY | -12.53% |
| 2020 Q4 | 1.08 Billion CNY | 86.45% |
| 2020 Q1 | 496.18 Million CNY | 7.44% |
| 2019 FY | 461.8 Million CNY | -48.52% |
| 2019 Q3 | 496.41 Million CNY | -18.44% |
| 2019 Q4 | 461.8 Million CNY | -6.97% |
| 2019 Q1 | 794.62 Million CNY | -11.42% |
| 2019 Q2 | 608.65 Million CNY | -23.4% |
| 2018 Q4 | 897.11 Million CNY | -11.86% |
| 2018 FY | 897.11 Million CNY | -33.0% |
| 2018 Q1 | 970 Million CNY | -27.55% |
| 2018 Q2 | 1.04 Billion CNY | 8.12% |
| 2018 Q3 | 1.01 Billion CNY | -2.95% |
| 2017 Q4 | 1.33 Billion CNY | 3.62% |
| 2017 FY | 1.33 Billion CNY | 11.67% |
| 2017 Q3 | 1.29 Billion CNY | 1.38% |
| 2017 Q2 | 1.27 Billion CNY | 0.44% |
| 2017 Q1 | 1.26 Billion CNY | 5.82% |
| 2016 FY | 1.19 Billion CNY | -8.39% |
| 2016 Q4 | 1.19 Billion CNY | -9.68% |
| 2016 Q3 | 1.32 Billion CNY | 0.66% |
| 2016 Q2 | 1.31 Billion CNY | -6.42% |
| 2016 Q1 | 1.4 Billion CNY | 7.68% |
| 2015 FY | 1.3 Billion CNY | 14.62% |
| 2015 Q1 | 1.18 Billion CNY | 3.45% |
| 2015 Q2 | 1.17 Billion CNY | -0.28% |
| 2015 Q3 | 1.13 Billion CNY | -4.07% |
| 2015 Q4 | 1.3 Billion CNY | 15.82% |
| 2014 Q1 | 797.9 Million CNY | -12.08% |
| 2014 FY | 1.14 Billion CNY | 25.82% |
| 2014 Q3 | 943.27 Million CNY | 18.32% |
| 2014 Q2 | 797.21 Million CNY | -0.09% |
| 2014 Q4 | 1.14 Billion CNY | 21.06% |
| 2013 Q3 | 565.5 Million CNY | 5.95% |
| 2013 Q4 | 907.55 Million CNY | 60.48% |
| 2013 FY | 907.55 Million CNY | 103.63% |
| 2013 Q1 | 590.4 Million CNY | 32.47% |
| 2013 Q2 | 533.73 Million CNY | -9.6% |
| 2012 Q1 | 235.79 Million CNY | 322.77% |
| 2012 Q4 | 445.69 Million CNY | 5.58% |
| 2012 FY | 445.69 Million CNY | 699.1% |
| 2012 Q3 | 422.12 Million CNY | 637.44% |
| 2012 Q2 | 57.24 Million CNY | -75.72% |
| 2011 Q1 | 40.07 Million CNY | -15.8% |
| 2011 FY | 55.77 Million CNY | 17.18% |
| 2011 Q3 | 32.48 Million CNY | -16.04% |
| 2011 Q2 | 38.69 Million CNY | -3.45% |
| 2011 Q4 | 55.77 Million CNY | 71.7% |
| 2010 Q2 | 326.65 Million CNY | 0.0% |
| 2010 Q4 | 47.59 Million CNY | -38.55% |
| 2010 Q3 | 77.45 Million CNY | -76.29% |
| 2010 FY | 47.59 Million CNY | -85.22% |
| 2009 Q4 | 321.98 Million CNY | 0.0% |
| 2009 FY | 321.98 Million CNY | 12.46% |
| 2008 FY | 286.3 Million CNY | 61.29% |
| 2007 FY | 177.5 Million CNY | 0.0% |